Tuesday’s Midday Stock Update: NovaBay Pharma (NBY), Anthera Pharmaceuticals (ANTH), uniQure NV (QURE), Fuelcell Energy (FCEL), Organovo Holdings (ONVO)

By Carrie Williams

So far Tuesday, June 11, NASDAQ is down -3.19% and the S&P is down -2.41%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; NovaBay Pharma (NBYResearch Report), Anthera Pharmaceuticals (ANTHResearch Report), uniQure NV (QUREResearch Report), Fuelcell Energy (FCELResearch Report) and Organovo Holdings (ONVOResearch Report).

NovaBay Pharma is down -48.27% in midday trading to $2.09. Shares opened today at $4.04. The company has a 52-week low of $0.23 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.25, marking a -69.06% potential downside from current levels. In a report issued on March 29, H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on NBY, with a price target of $1, which implies a downside of 75% from current levels.

Anthera Pharmaceuticals is up 28.32% in midday trading to $0.06. Shares opened today at $0.05. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

uniQure NV is down -12.98% in midday trading to $65.82. Shares opened today at $75.64. The company has a 52-week low of $21.98 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $93.71, marking a 23.89% potential upside from current levels. In a report issued on May 22, Chardan analyst Gbola Amusa reiterated a Buy rating on QURE, with a price target of $175, which implies an upside of 131% from current levels. Over the last 3 months, the insider sentiment on uniQure NV has been negative based on 34 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Fuelcell Energy is down -11.96% in midday trading to $0.41. Shares opened today at $0.46. The company has a 52-week low of $0.39 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.00, marking a 117.39% potential upside from current levels. In a report issued on June 6, Oppenheimer analyst Colin Rusch downgraded FCEL to Hold.

See today’s analyst top recommended stocks >>

Organovo Holdings is down -10.21% in midday trading to $0.52. Shares opened today at $0.58. The company has a 52-week low of $0.37 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.50, marking a 156.63% potential upside from current levels. In a report issued on May 24, H.C. Wainwright analyst Ed Arce maintained a Buy rating on ONVO, with a price target of $1.50, which implies an upside of 157% from current levels. Separately, on May 23, Jones Trading’s Matthew Cross downgraded the stock to Hold . In the last 30 days, insiders have sold $40.9K worth of ONVO shares.

Trending Stocks Based on Insider Activity >>